EJXB Stock Chart & Stats
€4.77
>-€0.01(-0.14%)
At close: 4:00 PM EDT
€4.77
>-€0.01(-0.14%)
Day’s Range― - ―
52-Week Range€3.73 - €5.81
Previous CloseN/A
Volume0.00
Average Volume (3M)180.00
Market Cap
€2.06B
Enterprise Value€23.05B
Total Cash (Recent Filing)€2.31B
Total Debt (Recent Filing)€6.83B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 25, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding368,587,650
10 Day Avg. Volume435
30 Day Avg. Volume180
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.88
Price to Sales (P/S)1.22
P/FCF Ratio8.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.15Price Target Upside-12.93% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.37
Revenue Forecast (FY)€1.56B
Bulls Say, Bears Say
Bulls Say
Recurring Installed-Base RevenueElekta’s installed base of long-lived radiation-therapy systems supports recurring service, maintenance, and upgrade revenue beyond initial equipment sales. This creates customer continuity and a more durable revenue foundation, helping partly offset fluctuations in hospital capital spending.
Strong Free Cash FlowStrong recent operating and free cash flow provides internally generated funding for service operations, product investment, and financial obligations despite reported losses. The 16.1% TTM free-cash-flow increase is a meaningful cash-generation strength over the next several quarters.
Stable Gross MarginA gross margin holding near 37% indicates that the economics of Elekta’s products and services have remained comparatively resilient even as revenue and operating profit weakened. Preserving this level supports the possibility of restoring operating leverage if demand improves.
Bears Say
Revenue And Profitability DeclineThe sharp TTM revenue contraction and move to a net loss represent a material deterioration in the earnings base. Continued weakness could reduce resources available for research, commercial execution, and debt service while making recovery dependent on renewed order growth.
Higher Leverage And Lower EquityDebt now exceeds equity and the equity base has contracted substantially, reducing balance-sheet flexibility compared with prior years. This leaves Elekta with less capacity to absorb prolonged operating weakness or pursue investment while maintaining shareholder returns.
Operating Margin CompressionThe decline in EBIT margin shows that weaker revenue is translating into materially lower operating profitability rather than being absorbed without consequence. Combined with modest cash flow relative to revenue, this suggests limited operating leverage if sales remain subdued.
Elekta AB News
EJXB FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was €3.73 and its highest was €5.80 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is €2.06B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Nov 25, 2026 which is in 26 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Aug 27, 2026. The company reported €0.062 earnings per share for the quarter, beating the consensus estimate of €0.042 by €0.02.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB does not currently pay dividends.
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate is 0.08.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of €0.062 in its last earnings report, beating expectations of €0.042. Following the earnings report the stock price went down -5.761%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in DE:EJXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elekta AB
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
EJXB Stock 12 Month Forecast
Average Price Target
€4.15
▼(-12.93% Downside)
Technical Analysis
Stille AB
―
Surgical Science Sweden AB
―
OssDsign AB
―
Corline Biomedical AB
―
FluoGuide A/S
―